Cancer

Items 11-20 of 31

per page
Set Descending Direction
  1. Everolimus
    CAS  159351-69-6
    AG-CN2-0520
    AG-CN2-0520-M0011 mg
    CHF 40.00
    AG-CN2-0520-M0055 mg
    CHF 75.00
    AG-CN2-0520-M02525 mg
    CHF 195.00
    Everolimus
  2. FK-866
    CAS  658084-64-1
    AG-CR1-0011
    AG-CR1-0011-M0011 mg
    CHF 55.00
    AG-CR1-0011-M0055 mg
    CHF 120.00
    FK-866
  3. Heptelidic acid
    CAS  57710-57-3 (74310-84-2 deleted)
    AG-CN2-0118
    AG-CN2-0118-C250250 µg
    CHF 140.00
    AG-CN2-0118-M0011 mg
    CHF 420.00
    Heptelidic acid
  4. Inosine
    CAS  58-63-9
    AG-CR1-3554
    AG-CR1-3554-M100100 mg
    CHF 25.00
    AG-CR1-3554-M500500 mg
    CHF 40.00
    AG-CR1-3554-G0011 g
    CHF 65.00
    Inosine
  5. Lipofermata
    CAS  297180-15-5
    AG-CR1-3542
    AG-CR1-3542-M01010 mg
    CHF 90.00
    AG-CR1-3542-M05050 mg
    CHF 270.00
    Lipofermata
  6. Liraglutide
    CAS  204656-20-2
    AG-CP3-0034
    AG-CP3-0034-M0011 mg
    CHF 60.00
    AG-CP3-0034-M0055 mg
    CHF 160.00
    AG-CP3-0034-M02525 mg
    CHF 450.00
    AG-CP3-0034-M100100 mg
    CHF 1'100.00

    BULK available!
    Research Use Only (RUO). NOT ALLOWED FOR USE IN HUMANS.

    Learn more about GLP-1 & GIP Receptor Agonists

    Liraglutide
  7. MOTS-c (human)
    CAS  1627580-64-6
    AG-CP3-0026
    AG-CP3-0026-M0011 mg
    CHF 180.00
    AG-CP3-0026-M0055 mg
    CHF 630.00
    MOTS-c (human)
  8. MOTS-c (K14Q Mutant) (human)
    AG-CP3-0033
    AG-CP3-0033-M0011 mg
    CHF 180.00
    AG-CP3-0033-M0055 mg
    CHF 630.00
    MOTS-c (K14Q Mutant) (human)
  9. Mubritinib
    CAS  366017-09-6
    AG-CR1-3755
    AG-CR1-3755-M0055 mg
    CHF 35.00
    AG-CR1-3755-M02525 mg
    CHF 140.00
    Mubritinib
  10. N1-Guanyl-1,7-diaminoheptane [GC7]
    CAS  150417-90-6 (parent 150333-69-0)
    AG-CR1-3702
    AG-CR1-3702-M01010 mg
    CHF 140.00
    AG-CR1-3702-M05050 mg
    CHF 420.00
    N1-Guanyl-1,7-diaminoheptane [GC7]

Items 11-20 of 31

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.